Analyst on FDA proposal: Ball is in hearing aid industry's court

On Tuesday, the FDA revealed its proposed guidelines meant to improve the access to affordable hearing aids for Americans. Following the proposal, which did not contain any surprises, it is now the hearing aid industry's move, says an analyst at DNB Markets.

Photo: Jacquelyn Martin/AP/Ritzau Scanpix

On Tuesday, the US Drug and Food Administration (FDA) presented its proposed guidelines for the upcoming over-the-counter (OTC) sales channel of hearing aids.

The FDA proposal comes after a July executive order by US President Joe Biden, in which he directed the agency to prepare for the future OTC channel for hearing aids sold without a prescription or need to see an audiologist.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs